Correlation Between Genscript Biotech and Keros Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Genscript Biotech and Keros Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Genscript Biotech and Keros Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Genscript Biotech and Keros Therapeutics, you can compare the effects of market volatilities on Genscript Biotech and Keros Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Genscript Biotech with a short position of Keros Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Genscript Biotech and Keros Therapeutics.

Diversification Opportunities for Genscript Biotech and Keros Therapeutics

0.49
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Genscript and Keros is 0.49. Overlapping area represents the amount of risk that can be diversified away by holding Genscript Biotech and Keros Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Keros Therapeutics and Genscript Biotech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Genscript Biotech are associated (or correlated) with Keros Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Keros Therapeutics has no effect on the direction of Genscript Biotech i.e., Genscript Biotech and Keros Therapeutics go up and down completely randomly.

Pair Corralation between Genscript Biotech and Keros Therapeutics

Assuming the 90 days horizon Genscript Biotech is expected to generate 0.45 times more return on investment than Keros Therapeutics. However, Genscript Biotech is 2.23 times less risky than Keros Therapeutics. It trades about 0.15 of its potential returns per unit of risk. Keros Therapeutics is currently generating about -0.28 per unit of risk. If you would invest  127.00  in Genscript Biotech on November 5, 2024 and sell it today you would earn a total of  9.00  from holding Genscript Biotech or generate 7.09% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy95.0%
ValuesDaily Returns

Genscript Biotech  vs.  Keros Therapeutics

 Performance 
       Timeline  
Genscript Biotech 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Genscript Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest fragile performance, the Stock's basic indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders.
Keros Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Keros Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Genscript Biotech and Keros Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Genscript Biotech and Keros Therapeutics

The main advantage of trading using opposite Genscript Biotech and Keros Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Genscript Biotech position performs unexpectedly, Keros Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Keros Therapeutics will offset losses from the drop in Keros Therapeutics' long position.
The idea behind Genscript Biotech and Keros Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Other Complementary Tools

Content Syndication
Quickly integrate customizable finance content to your own investment portal
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments